Management and Amelioration of Knee Joint Osteoarthritis in Adults Using a Novel High-Functional Bovine Collagen Peptide As a Nutritional Therapy: A Double-Blind, Prospective, Multicentric, Randomized, Active and Placebo Controlled, Five-Arm,...

Overview

Journal Cartilage

Date 2024 Jan 18

PMID 38235711

Authors

Sheena Devasia

Jinu T Joseph

Stephena P S

Seiko Koizumi

Liz Clarke

Sriraam V T

Abhilash Parameswaran Kailas

Shajil Madhavan

Affiliations

Soon will be listed here.

Abstract

Objective: The various functionalities of collagen peptides have generated a large interest in utilizing the bioactive peptides as a nutritional therapy to ameliorate various physiological degenerative conditions. Collagen peptides are observed to reduce the pain and aligned difficulties with respect to osteoarthritis. Here we report the enhanced ameliorating property of novel high-functional "Wellnex" Type J collagen peptides following a double-blind randomized active and placebo-controlled 5-arm clinical trial ( = 100) by using it as a nutritional supplement in subjects with knee joint osteoarthritis in comparison with conventional bovine collagen peptides. The efficacy, safety, and tolerability were also studied.

Design: Dosages of 2.5, 5.0, and 10.0 g of high-functional Type J bovine collagen peptides, 10.0 g of conventional collagen peptides, and 10.0 g of placebo were given to the 5 groups for a period of 90 days. The Western Ontario McMaster Universities Arthritis Index (WOMAC) score, Pain Scale, Quality of Life (QoL), Physician's Impression of change Score (PICS), serum C-terminal cross-linked telopeptide of type II collagen (CTX-II) levels and Magnetic Resonance Imaging Osteoarthritis Knee Score (MOAKS) parameters were monitored.

Results: Type J 2.5 g showed significant improvement in WOMAC, QoL, CTX, and MOAKS and observed to be equivalent to conventional collagen peptide 10-g supplementation in terms of efficacy.

Conclusion: The two significant outcomes of the study were that Type J 10.0 g, Type J 5.0 g, Type J 2.5 g and conventional collagen peptides 10.0 g supplementation were observed to be beneficial nutraceutical therapies for knee joint osteoarthritis, and Type J 2.5 g supplementation was equivalent to conventional collagen peptides 10.0-g supplementation in terms of efficacy.

Citing Articles

The Effects of Type I Collagen Hydrolysate Supplementation on Bones, Muscles, and Joints: A Systematic Review.

Brueckheimer P, Costa Silva T, Rodrigues L, Zague V, Isaia Filho C Orthop Rev (Pavia). 2025; 17:129086.

PMID: 39980497 PMC: 11842160. DOI: 10.52965/001c.129086.

References

Bruyere O, Zegels B, Leonori L, Rabenda V, Janssen A, Bourges C . Effect of collagen hydrolysate in articular pain: a 6-month randomized, double-blind, placebo controlled study. Complement Ther Med. 2012; 20(3):124-30. DOI: 10.1016/j.ctim.2011.12.007. View

McAlindon T, Nuite M, Krishnan N, Ruthazer R, Price L, Burstein D . Change in knee osteoarthritis cartilage detected by delayed gadolinium enhanced magnetic resonance imaging following treatment with collagen hydrolysate: a pilot randomized controlled trial. Osteoarthritis Cartilage. 2011; 19(4):399-405. DOI: 10.1016/j.joca.2011.01.001. View

Hawker G, Mian S, Kendzerska T, French M . Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain.... Arthritis Care Res (Hoboken). 2012; 63 Suppl 11:S240-52. DOI: 10.1002/acr.20543. View

Benito-Ruiz P, Camacho-Zambrano M, Carrillo-Arcentales J, Mestanza-Peralta M, Vallejo-Flores C, Vargas-Lopez S . A randomized controlled trial on the efficacy and safety of a food ingredient, collagen hydrolysate, for improving joint comfort. Int J Food Sci Nutr. 2009; 60 Suppl 2:99-113. DOI: 10.1080/09637480802498820. View

Blanco F, Rego I, Ruiz-Romero C . The role of mitochondria in osteoarthritis. Nat Rev Rheumatol. 2011; 7(3):161-9. DOI: 10.1038/nrrheum.2010.213. View

Leon-Lopez A, Morales-Penaloza A, Martinez-Juarez V, Vargas-Torres A, Zeugolis D, Aguirre-Alvarez G . Hydrolyzed Collagen-Sources and Applications. Molecules. 2019; 24(22). PMC: 6891674. DOI: 10.3390/molecules24224031. View

Aigner T, Rose J, Martin J, Buckwalter J . Aging theories of primary osteoarthritis: from epidemiology to molecular biology. Rejuvenation Res. 2004; 7(2):134-45. DOI: 10.1089/1549168041552964. View

Ohara H, Matsumoto H, Ito K, Iwai K, Sato K . Comparison of quantity and structures of hydroxyproline-containing peptides in human blood after oral ingestion of gelatin hydrolysates from different sources. J Agric Food Chem. 2007; 55(4):1532-5. DOI: 10.1021/jf062834s. View

Deal C, Moskowitz R . Nutraceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chondroitin sulfate, and collagen hydrolysate. Rheum Dis Clin North Am. 1999; 25(2):379-95. DOI: 10.1016/s0889-857x(05)70074-0. View

10.

Nakatani S, Mano H, Sampei C, Shimizu J, Wada M . Chondroprotective effect of the bioactive peptide prolyl-hydroxyproline in mouse articular cartilage in vitro and in vivo. Osteoarthritis Cartilage. 2009; 17(12):1620-7. DOI: 10.1016/j.joca.2009.07.001. View

11.

Huang C, Lai K, Hung L, Wu W, Liu F, Ho L . Advanced glycation end products cause collagen II reduction by activating Janus kinase/signal transducer and activator of transcription 3 pathway in porcine chondrocytes. Rheumatology (Oxford). 2011; 50(8):1379-89. DOI: 10.1093/rheumatology/ker134. View

12.

Ichikawa S, Morifuji M, Ohara H, Matsumoto H, Takeuchi Y, Sato K . Hydroxyproline-containing dipeptides and tripeptides quantified at high concentration in human blood after oral administration of gelatin hydrolysate. Int J Food Sci Nutr. 2009; 61(1):52-60. DOI: 10.3109/09637480903257711. View

13.

Wang L, Wang Q, Liang Q, He Y, Wang Z, He S . Determination of bioavailability and identification of collagen peptide in blood after oral ingestion of gelatin. J Sci Food Agric. 2014; 95(13):2712-7. DOI: 10.1002/jsfa.7008. View

14.

Bellamy N, BUCHANAN W, Goldsmith C, Campbell J, Stitt L . Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988; 15(12):1833-40. View

15.

Aito-Inoue M, Ohtsuki K, Nakamura Y, Park E, Iwai K, Morimatsu F . Improvement in isolation and identification of food-derived peptides in human plasma based on precolumn derivatization of peptides with phenyl isothiocyanate. J Agric Food Chem. 2006; 54(15):5261-6. DOI: 10.1021/jf060531s. View

16.

Loeser R . Aging processes and the development of osteoarthritis. Curr Opin Rheumatol. 2012; 25(1):108-13. PMC: 3713615. DOI: 10.1097/BOR.0b013e32835a9428. View

17.

Shigemura Y, Iwai K, Morimatsu F, Iwamoto T, Mori T, Oda C . Effect of Prolyl-hydroxyproline (Pro-Hyp), a food-derived collagen peptide in human blood, on growth of fibroblasts from mouse skin. J Agric Food Chem. 2009; 57(2):444-9. DOI: 10.1021/jf802785h. View

18.

Rabin R, de Charro F . EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001; 33(5):337-43. DOI: 10.3109/07853890109002087. View

19.

Mobasheri A, Mahmoudian A, Kalvaityte U, Uzieliene I, Larder C, Iskandar M . A White Paper on Collagen Hydrolyzates and Ultrahydrolyzates: Potential Supplements to Support Joint Health in Osteoarthritis?. Curr Rheumatol Rep. 2021; 23(11):78. PMC: 8556166. DOI: 10.1007/s11926-021-01042-6. View

20.

Messai H, Duchossoy Y, Khatib A, Panasyuk A, Mitrovic D . Articular chondrocytes from aging rats respond poorly to insulin-like growth factor-1: an altered signaling pathway. Mech Ageing Dev. 2000; 115(1-2):21-37. DOI: 10.1016/s0047-6374(00)00107-x. View